Liquid gold label for near-tumor development as well as use method and application of liquid gold label

Abstract

The invention relates to the technical field of developing gold labels, and discloses a near-tumor developing liquid gold label and a using method and application thereof.The near-tumor developing liquid gold label comprises a mixed solution composed of iodine oil and biological hemostatic glue, the iodine content of the iodine oil is not smaller than 40%, and the biological hemostatic glue is selected from fibrin glue and gelatin-based hemostatic glue. The mass ratio of the iodine oil to the biological hemostatic glue is 1: 1-1: 2; the liquid gold label provided by the invention has remarkable economical efficiency, and the production and implantation cost of the gold label is reduced, so that the liquid gold label is widely applied in clinic; meanwhile, due to the adoption of a non-metal material, the risk of in-vivo implantation is reduced, the occurrence rate of complications such as infection and bleeding is reduced, and the safety and acceptance of a patient are improved; besides, the liquid gold label does not generate artifacts in imaging examination, so that accurate judgment of a doctor on the position and the form of the tumor is ensured, and the accuracy and the safety of SBRT are improved.

Description

Technical Field

[0001] The present invention relates to the technical field of gold label imaging, and more particularly to a liquid gold label for tumor adjacent imaging, and a use method and application thereof. Background Art

[0002] In radiotherapy, especially stereotactic body radiotherapy (SBRT), precise positioning and registration are key to ensuring treatment efficacy and patient safety. Traditionally, gold labels (such as metal markers) have been widely used in the body as positioning landmarks to provide clear references during imaging examinations. However, the use of gold labels faces many challenges in clinical practice. Although existing gold label implantation technology can provide high-precision positioning, its popularity is limited, mainly due to factors such as the high cost of gold labels, implantation risks, and patient acceptance.

[0003] However, the materials of existing gold labels usually contain metal substances. The presence of metal substances in the body after the gold label is implanted may affect subsequent imaging examinations, especially in magnetic resonance imaging (MRI). Metal substances may cause artifacts and affect image quality. Summary of the Invention

[0004] The present invention provides a liquid gold label for tumor imaging and its use method and application, so as to solve the problem that the material of the gold label in the prior art usually contains metal substances, which may cause artifacts in magnetic resonance imaging (MRI) and affect image quality.

[0005] In order to achieve the above object, the present invention provides the following technical solutions:

[0006] A liquid gold label for tumor-adjacent imaging, a method for using the label, and an application thereof, comprises a mixture of iodized oil and biological hemostatic glue, wherein the iodized oil contains no less than 40% iodine, and the biological hemostatic glue is selected from the following types: fibrin glue and gelatin-based hemostatic glue, and the mass ratio of the iodized oil to the biological hemostatic glue is between 1:1 and 1:2.

[0007] Preferably, the liquid gold label is used in tumor radiotherapy, especially in the field of stereotactic radiotherapy.

[0008] Preferably, the iodized oil and the biological hemostatic glue are both drawn into the same needle tube in sequence using a 1 ml syringe and mixed, the mixing time of the mixed solution is not less than 2 seconds, and the mixing temperature is not less than 0 degrees Celsius.

[0009] Preferably, the mixed liquid is in a flocculent state after mixing, and the maximum storage time of the mixed liquid is 2 hours.

[0010] Preferably, the total amount of the mixed solution used for a single injection is 0.2-0.3 ml, and the mixed solution syringe is a 1 ml syringe.

[0011] Preferably, the injection position of the mixed solution is guided by CT, and the injection needle is a puncture needle or an intracardiac injection needle.

[0012] Preferably, contraindications for the use of the mixed solution include: patients being allergic to iodine.

[0013] Preferably, S1, selecting a gold label implantation site; S2, preparing an implantation device; S3, preparing a mixed solution; S4, injecting the liquid gold label; S5, observing and evaluating.

[0014] Preferably, the selection of the gold marker implantation site includes determining the specific location and morphology of the tumor through imaging examination; selecting a suitable gold marker implantation site based on the size, shape of the tumor and its relationship with surrounding tissues; and the site can achieve optimal positioning and registration effects in subsequent radiotherapy.

[0015] Preferably, the preparation of the implantation device includes preparing a puncture needle or an intracardiac injection needle, ensuring that it is sterile and suitable for the selected implantation site; and preparing a 1 ml syringe for extracting and injecting the liquid gold label mixture.

[0016] Preferably, the preparation of the mixed solution includes using a 1 ml syringe to draw 0.1-0.2 ml of iodized oil, and continuing to draw 0.1-0.2 ml of biological hemostatic glue injection in the same syringe until the iodized oil and the biological hemostatic glue are fully mixed to form a uniform mixed solution.

[0017] Preferably, the injection of the liquid gold label includes, under CT guidance, accurately delivering the puncture needle or intracardiac injection needle to the previously selected gold label implantation site; after ensuring the accurate position of the needle tip, slowly injecting the prepared mixed solution into the body through the end of the puncture needle or intracardiac injection needle; until the mixed solution forms a stable jelly-like micro-mass in the tissue.

[0018] Preferably, the observation and evaluation include the doctor performing regular imaging examinations on the patient after injection to evaluate the stability of the liquid gold label and its imaging effect in the body, to ensure that the gold label can effectively provide positioning support in subsequent radiotherapy and will not produce metal artifacts.

[0019] The principle and beneficial effects of this technical solution:

[0020] (1) Compared with traditional metal gold labels, the liquid gold label provided by the present invention significantly reduces the implantation cost and has significant economic benefits for patients with relevant needs. By reducing the production and implantation costs of the gold label, the clinical popularity of the gold label is greatly increased, making its application in clinical practice more extensive while increasing the implantation experience of medical staff, further improving the safety of the liquid gold label.

[0021] (2) The liquid gold label in the present invention is made of non-metallic materials. Therefore, compared with traditional solid metal materials, the liquid gold label does not require invasive operations during the implantation process. The liquid gold label can be implanted by injection, which greatly reduces the risk of implantation in the body, reduces the incidence of complications such as infection and bleeding, and improves the safety of patients. At the same time, the absence of metal materials can eliminate patients' concerns about the implantation of metal substances in the body and prevent patients from refusing to accept related treatments due to psychological factors.

[0022] (3) Since the liquid gold label in the present invention does not use metal materials, it will not produce artifacts in imaging examinations after implantation. It can ensure that doctors can accurately judge the location and morphology of tumors in imaging examinations such as magnetic resonance imaging, thereby optimizing the conditions for doctors to formulate treatment plans and improving the accuracy and safety of SBRT. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 This is a diagram of the development results of the present invention under imaging examination;

[0024] Figure 2 This is the image of the development result of traditional gold label under imaging examination; DETAILED DESCRIPTION

[0025] The present invention will be further described in detail below with reference to the accompanying drawings and embodiments:

[0026] Example:

[0027] like Figure 1 and Figure 2 As shown, the present invention provides a liquid gold label for tumor-adjacent imaging and its use method and application, including a mixture of iodized oil and biological hemostatic glue, the iodine content of the iodized oil is not less than 40%, the types of biological hemostatic glue selected include fibrin glue and gelatin-based hemostatic glue, and the mass ratio of iodized oil to biological hemostatic glue is between 1:1 and 1:2.

[0028] like Figure 1 and Figure 2 As shown, iodized oil and biological hemostatic glue are successively drawn into the same needle tube using a 1 ml syringe and mixed, the mixing time of the mixed solution is not less than 2 seconds, and the mixing temperature is not less than 0 degrees Celsius.

[0029] like Figure 1 and Figure 2 As shown, iodized oil and biological hemostatic glue are successively drawn into the same needle tube using a 1 ml syringe and mixed, the mixing time of the mixed solution is not less than 2 seconds, and the mixing temperature is not less than 0 degrees Celsius.

[0030] like Figure 1 and Figure 2 As shown, the mixed solution is in a flocculent state after mixing, and the maximum storage time of the mixed solution is 2h.

[0031] like Figure 1 and Figure 2 As shown, the total amount of mixed solution used for a single injection is 0.2-0.3 ml, and the mixed solution syringe is a 1 ml syringe.

[0032] like Figure 1 and Figure 2 As shown, the injection position of the mixed solution is guided by CT, and the injection needle uses a puncture needle or an intracardiac injection needle.

[0033] like Figure 1 and Figure 2 As shown, contraindications for the use of the mixture include: patients with iodine allergy.

[0034] The specific usage and function of this embodiment are as follows:

[0035] A method for using a liquid gold label for tumor-adjacent imaging comprises the following steps:

[0036] S1. Select the gold label implantation site; S2. Prepare the implantation equipment; S3. Prepare the mixed solution; S4. Inject the liquid gold label; S5. Observe and evaluate.

[0037] The implantation of the mixed liquid includes the following steps: selecting the gold label implantation site, including determining the specific location and morphology of the tumor through imaging examination; selecting a suitable gold label implantation site based on the size, shape of the tumor and its relationship with surrounding tissues; this site can achieve the best positioning and alignment effect in subsequent radiotherapy.

[0038] Preparing the implant device includes preparing a puncture needle or intracardiac injection needle, ensuring that it is sterile and suitable for the selected implantation site; preparing a 1ml syringe for withdrawing and injecting the liquid gold label mixture.

[0039] The preparation of the mixed solution includes using a 1 ml syringe to draw 0.1-0.2 ml of iodized oil, and continuing to draw 0.1-0.2 ml of biological hemostatic glue injection in the same syringe until the iodized oil and the biological hemostatic glue are fully mixed to form a uniform mixed solution.

[0040] The injection of liquid gold label includes accurately delivering the puncture needle or intracardiac injection needle to the previously selected gold label implantation site under CT guidance; after ensuring the accurate position of the needle tip, the prepared mixture is slowly injected into the body through the end of the puncture needle or intracardiac injection needle; until the mixture forms a stable jelly-like tiny mass in the tissue.

[0041] Observation and evaluation include regular imaging examinations of patients by doctors after injection to evaluate the stability of the liquid gold label and its imaging effect in the body, to ensure that the gold label can effectively provide positioning support in subsequent radiotherapy and will not produce metal artifacts.

[0042] The above is only an embodiment of the present invention, and the common knowledge such as the specific technical solutions and / or characteristics in the solution are not described in detail here. It should be pointed out that for those skilled in the art, without departing from the technical solution of the present invention, several variations and improvements can be made, which should also be regarded as the scope of protection of the present invention, and these will not affect the effect of the implementation of the present invention and the practicality of the patent. The scope of protection required by this application shall be based on the content of its claims, and the specific implementation methods and other records in the description can be used to interpret the content of the claims.

Claims

1. A liquid gold label for tumor-adjacent imaging, characterized by: The invention comprises a mixed liquid consisting of iodized oil and biological hemostatic glue, wherein the iodine content of the iodized oil is not less than 40%, the biological hemostatic glue includes fibrin glue and gelatin-based hemostatic glue, and the mass ratio of the iodized oil to the biological hemostatic glue is between 1:1 and 1:

2.

2. A use of the liquid gold label for tumor-adjacent imaging according to claim 1, characterized in that: The liquid gold label is used in tumor radiotherapy, especially in the field of stereotactic radiotherapy.

3. The method for using a liquid gold label for tumor-adjacent imaging according to claim 1, characterized in that: The iodized oil and the biological hemostatic glue are both sucked into the same needle tube in sequence using a 1 ml syringe and mixed. The mixing time of the mixed solution is not less than 2 seconds, and the mixing temperature is not less than 0 degrees Celsius.

4. The method for using a liquid gold label for tumor-adjacent imaging according to claim 1, characterized in that: The mixed solution is in a flocculent state after mixing, and the maximum storage time of the mixed solution is 2 hours.

5. The method for using a liquid gold label for tumor-adjacent imaging according to claim 1, characterized in that: The total amount of the mixed solution used for a single injection is 0.2-0.3 ml, and the mixed solution syringe is a 1 ml syringe.

6. The method for using a liquid gold label for tumor-adjacent imaging according to claim 1, characterized in that: The injection position of the mixed solution is guided by CT, and the injection needle is a puncture needle or an intracardiac injection needle.

7. The method for using a liquid gold label for tumor-adjacent imaging according to claim 1, characterized in that: Contraindications for the use of the mixture include: patients with iodine allergy.

8. The method for using a liquid gold label for tumor-adjacent imaging according to claim 1, characterized in that: The following steps are involved: S1. Select the gold label implantation site; S2. Prepare the implantation equipment; S3. Prepare the mixed solution; S4. Inject the liquid gold label; S5. Observation and evaluation.

9. The method for using a liquid gold label for tumor-adjacent imaging according to claim 8, characterized in that: The mixed liquid implantation includes the following steps: selecting the gold label implantation site includes determining the specific location and morphology of the tumor through imaging examination; selecting a suitable gold label implantation site based on the size and shape of the tumor and its relationship with surrounding tissues; and the site can achieve the best positioning and alignment effect in subsequent radiotherapy.

10. The liquid gold label for tumor-adjacent imaging and its use and application according to claim 9, characterized in that: The preparation of the implantation device includes preparing a puncture needle or an intracardiac injection needle, ensuring that the needle is sterile and suitable for the selected implantation site; Prepare a 1 ml syringe for extracting and injecting the liquid gold label mixture.

11. The liquid gold label for tumor imaging according to claim 9, and its use method and application, characterized in that: The preparation of the mixed solution includes using a 1 ml syringe to draw 0.1-0.2 ml of iodized oil, and continuing to draw 0.1-0.2 ml of biological hemostatic glue injection in the same syringe until the iodized oil and the biological hemostatic glue are fully mixed to form a uniform mixed solution.

12. The liquid gold label for tumor imaging according to claim 9, and its use method and application, is characterized in that: The injection of the liquid gold label includes, under CT guidance, accurately delivering the puncture needle or intracardiac injection needle to the previously selected gold label implantation site; after ensuring the accurate position of the needle tip, slowly injecting the prepared mixed liquid into the body through the end of the puncture needle or intracardiac injection needle; until the mixed liquid forms a stable jelly-like tiny mass in the tissue.

13. The liquid gold label for tumor imaging according to claim 9, and its use method and application, is characterized in that: The observation and evaluation include regular imaging examinations of the patient by the doctor after the injection to evaluate the stability of the liquid gold label and its imaging effect in the body, to ensure that the gold label can effectively provide positioning support in subsequent radiotherapy and will not produce metal artifacts.

Images